Therefore, our results demonstrate that, unlike its role in established HCC, METTL3 has a tumor‐inhibitory effect on the occurrence of HCC in the early stages of its development, suggesting that future liver cancer treatments targeting METTL3 should consider the stage of tumor progression. This evidence concerns the gene METTL3 and liver cancer.